The link between NLRP3 and AD pathology has been demonstrated in other studies as well, where genetic deficiency and pharmacological inhibition of NLRP3 in mice over-expressing human amyloid precursor protein (APP) and presenilin 1 (PS1) reduces Aβ deposition and improves cognitive functions (Heneka et al., 2013; Dempsey et al., 2017; Yin J. et al., 2018). The gene discussed is PSEN1; the disease is Alzheimer disease.